Free Trial

Elicio Therapeutics Q3 2023 Earnings Report

Elicio Therapeutics EPS Results

Actual EPS
-$1.27
Consensus EPS
-$0.80
Beat/Miss
Missed by -$0.47
One Year Ago EPS
N/A

Elicio Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Elicio Therapeutics Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Elicio Therapeutics Earnings Headlines

Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong
Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.
JonesTrading Reaffirms Their Buy Rating on Elicio Therapeutics (ELTX)
Elicio Therapeutics Advances ELI-002 and Secures Funding
See More Elicio Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Elicio Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Elicio Therapeutics and other key companies, straight to your email.

About Elicio Therapeutics

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.

View Elicio Therapeutics Profile

More Earnings Resources from MarketBeat